The goal of this project is to create a novel siRNA delivery nanotechnology capable of treating and preventing the recurrence of glioblastoma, the most malignant primary human brain cancer. There is increasing evidence that brain tumor recurrence is due to the presence of brain tumor initiating cells (BTICs). These cells are believed to be able to survive conventional treatments and to be able to migrate away from the primary tumor site and form new tumors. RNA interference (RNAi), a natural cellular process that can prevent the expression of genes in a sequence-specific manner, can be induced by the introduction of short interfering RNA (siRNA) into the cells. Using siRNA to turn off the genes that allow BTICs to survive treatment, to migrate, and to form new tumors has the potential to prevent tumor recurrence following treatment. However, siRNA delivery is challenging. Viral siRNA delivery has many potential problems such as tumorigenicity and immunogenicity, and is generally limited to carrying one type of siRNA, as multiple doses could increase the risks of using them in patients. We have been able to synthesize a novel, bioreducible poly(beta-amino ester) (PBAE)-based nanoparticle capable of safe and effective delivery of siRNA to primary human glioblastoma cells. We have also shown that we can achieve near complete gene knockdown of a fluorescent marker gene using only a fraction of the siRNA that we can load into the nanoparticles. We have also completed in vitro work that suggests that these nanoparticles preferentially induce RNAi in BTICs and not in healthy human brain cells. We believe that we can even further optimize this delivery in a way that will enable delivery of multiple siRNAs simultaneously, and that we can determine the biological mechanism behind tumor selectivity. Based on our preliminary work, we hypothesize that we will be able to use these PBAE-based nanoparticles to codeliver multiple siRNAs within the same nanoparticle with the goal of simultaneously shutting down several biochemical pathways involved in tumor migration and growth. We hypothesize that this combinatorial approach will result in a robust phenotypic change that will prevent tumor recurrence and result in prolonged survival in a mouse model of brain cancer.
In Specific Aim 1 we will engineer PBAE nanoparticle chemistry to test our hypothesis that we can further optimize siRNA delivery.
In Specific Aim 2 we will determine the mechanism that enables tumor-specific delivery, and test the hypothesis that we can simultaneously and robustly knockdown the expression of multiple genes that promote tumor survival and prevent recurrence. Finally, in Specific Aim 3 we will examine the phenotypic change caused by knocking down the targeted genes both in vitro and in vivo to test the hypothesis that combinatorial, nanoparticle-mediated gene knockdown will slow tumor cell growth and tumor recurrence. This work will allow us to optimize and characterize a combinatorial, tumor-specific technology for the delivery of brain cancer therapeutics.

Public Health Relevance

This research is to develop a novel technology, nanoparticles that can safely and simultaneously deliver drugs to turn migratory and proliferative genes off in brain cancer cells, without altering healthy brain cells. This technology has the potential to trea brain cancer, prevent tumor recurrence, and thereby extend the survival of brain cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Predoctoral Individual National Research Service Award (F31)
Project #
5F31CA196163-02
Application #
9110710
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Korczak, Jeannette F
Project Start
2015-07-09
Project End
2017-07-08
Budget Start
2016-07-09
Budget End
2017-07-08
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Biomedical Engineering
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Lopez-Bertoni, Hernando; Kozielski, Kristen L; Rui, Yuan et al. (2018) Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival. Nano Lett 18:4086-4094
Kozielski, Kristen L; Rui, Yuan; Green, Jordan J (2016) Non-viral nucleic acid containing nanoparticles as cancer therapeutics. Expert Opin Drug Deliv 13:1475-87
Mangraviti, Antonella; Tzeng, Stephany Y; Gullotti, David et al. (2016) Non-virally engineered human adipose mesenchymal stem cells produce BMP4, target brain tumors, and extend survival. Biomaterials 100:53-66
Kozielski, Kristen L; Green, Jordan J (2016) Bioreducible Poly(Beta-Amino Ester)s for Intracellular Delivery of SiRNA. Methods Mol Biol 1364:79-87
Li, Xiaowei; Kozielski, Kristen; Cheng, Yu-Hao et al. (2016) Nanoparticle-mediated conversion of primary human astrocytes into neurons and oligodendrocytes. Biomater Sci 4:1100-12